BMJ

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Correspondence to Dr Lea Hoisnard, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris, Paris, Île-de-France, France; ...
BMJ

HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

10 Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK Correspondence to Dr Darren Plant, Centre for Musculoskeletal Research, ...
BMJ

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...
BMJ

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness

Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
BMJ

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo ...

Objectives Rheumatoid arthritis (RA) has a considerable disease burden with life-long physical limitations, reduced work productivity and high societal costs. Trials on arthralgia at-risk for RA are ...
BMJ

Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’

Correspondence to Xiaoqing Peng, Department of Obstetrics and Gynaecology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China; pengxiaoqing{at}ahmu.edu.cn We read with ...
BMJ

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA). Methods: All Assessment of SpondyloArthritis international Society ...
BMJ

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by ...

Rheumatology, Med Klinik I, Charité, Campus Benjamin Franklin, Berlin, Germany ...
BMJ

Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE

Objectives The goals of these studies were to elucidate the inter-relationships of specific anti-nuclear antibody (ANA), complement, and the interferon gene signature (IGS) in the pathogenesis of ...
BMJ

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...